Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、Leucovorin
Phase 3CompletedDevelopment Stage
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Jan 25, 2018 → Mar 10, 2022
About Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、Leucovorin
Irinotecan liposome、5-Fluorouracil、Leucovorin + Placebo、5-Fluorouracil、Leucovorin is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy. The current trial status is completed. This product is registered under clinical trial identifier NCT05074589. Target conditions include Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05074589 | Phase 3 | Completed |
Competing Products
2 competing products in Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZD6474 + Placebo + Docetaxel | Sanofi | Phase 2 | 51 |